- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00210860
An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.
An Open-label Study of the Safety and Efficacy of Topiramate for Migraine Prophylaxis: Extension Study to CAPSS-277
Studieoversikt
Detaljert beskrivelse
Migraine headaches can be disabling and can interfere with work and a person's quality of life. Preventing these headaches before they start is the best option. Topiramate, an anti-seizure medication, has been shown to help prevent migraine headaches from occurring. This is an open-label study that is an extension of a previous study (CAPSS-277) comparing topiramate and amitriptyline in migraine prevention. It includes patients who completed the previous study and elected to enter open label treatment with topiramate. The study will involve a 4-week Blinded Transition Phase during which patients will be titrated up to a daily topiramate dose of 100 milligrams (or the maximum tolerated dose, whichever is less). Then there will be a 12-week Open-Label Maintenance Phase during which the topiramate dose may be adjusted according to effectiveness and tolerance, but not to exceed a daily dose of 400 milligrams. While on topiramate, patients will record daily entries in their headache records. Patients will be asked questions to help assess their quality of life. Patients will also have physical examinations and laboratory tests performed during the study. The objective of this study is to evaluate the long-term safety and effectiveness of topiramate for the prevention of migraine headaches.
Topiramate oral tablets, 25 milligrams per tablet, will be given in the morning and evening to a dose not to exceed 400 milligrams per day or to the maximum tolerated dose, whichever is less
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of migraine with or without aura
- Successfully finished CAPSS-277 study
- In generally good health
- Able to take medicine orally
- If female, using birth control
Exclusion Criteria:
- Not having a more painful condition than the headache pain
- Cannot be taking any other medications not allowed by the study
- Abnormal liver tests
- Not compliant with study medication during the CAPSS-277 study
- Pregnant or breast-feeding
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Patient diary: number, duration, severity of headaches, symptoms, other medications used; QOL: Migraine Disability Assessment, Migraine-Specific Quality of Life, Quality of Life Enjoyment & Satisfaction Questionnaire-Short Form, Weight Satisfaction Scale
|
Sekundære resultatmål
Resultatmål |
---|
Adverse event reports; physical examinations; vital signs; electrocardiogram; laboratory tests for safety
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CR004669
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på topiramat
-
Johnson & Johnson Taiwan LtdFullført
-
Johnson & Johnson Pharmaceutical Research & Development...Fullført
-
Supernus Pharmaceuticals, Inc.Fullført
-
University of CopenhagenR W Johnson Pharmaceutical Research InstituteAvsluttet
-
Montefiore Medical CenterOrtho-McNeil PharmaceuticalFullført
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.FullførtOvervekt | Overstadig spiseforstyrrelse
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho-McNeil Neurologics, Inc.Fullført
-
Johnson & Johnson Pharmaceutical Research & Development...AvsluttetOvervekt | Diabetes mellitus, type 2 | Diabetes mellitus, voksendebut
-
Johnson & Johnson Pharmaceutical Research & Development...AvsluttetEn studie om effekt og sikkerhet av topiramat ved behandling av overvektige personer med dyslipidemiOvervekt | Hypertriglyseridemi | Høyt kolesterol
-
Johnson & Johnson Pharmaceutical Research & Development...FullførtEpilepsi | Anfall | Epilepsi, delvis